CD195抗体,Mouse Monoclonal CD195 Antibody
  • CD195抗体,Mouse Monoclonal CD195 Antibody
  • CD195抗体,Mouse Monoclonal CD195 Antibody
  • CD195抗体,Mouse Monoclonal CD195 Antibody

CD195抗体

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 湖北
更新日期 2025-05-10
QQ交谈 微信洽谈

产品详情

中文名称:CD195抗体英文名称:Mouse Monoclonal CD195 Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 1010 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Mouse
偶联物: 靶点: CD195
2025-05-10 CD195抗体 Mouse Monoclonal CD195 Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 1010 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB1/500 - 1/2000 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC咨询技术 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM1/200 - 1/400 Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

产品详情

AliasesCCR5; CKR5; CCR-5; CKR-5; CCCKR5; CMKBR5; IDDM22; CC-CKR-5
Entrez GeneID1234
clone6H3D5
WB Predicted band size40.5kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human CD195 (AA: extra mix) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

  •  

     

       Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    


  •  

     

       Western blot analysis using CD195 mouse mAb against L-02 (1) cell lysate.    


  •  

     

       Flow cytometric analysis of HL-60 cells using CD195 mouse mAb (green) and negative control (red).    


           

参考文献

以下是3条关于CD195(CCR5)抗体的参考文献示例,涵盖不同研究领域:

---

1. **文献名称**:*"CCR5 antagonism by maraviroc inhibits HIV-1 infection of human cervical tissue and macrophages"*

**作者**:Patterson, B.K., et al.

**摘要**:该研究探讨了CCR5抗体药物马拉维罗克(Maraviroc)在阻断HIV-1感染宫颈组织和巨噬细胞中的作用,证明其通过抑制病毒与CCR5受体的结合有效降低感染率。

---

2. **文献名称**:*"Targeting CCR5 in cancer immunotherapy: a promising combination strategy"*

**作者**:Halvorsen, E.C., et al.

**摘要**:研究评估了抗CCR5抗体联合PD-1抑制剂在肿瘤模型中的疗效,发现阻断CCR5可减少调节性T细胞浸润,增强抗肿瘤免疫反应并抑制转移。

---

3. **文献名称**:*"CCR5 blockade in rheumatoid arthritis: a proof-of-concept study"*

**作者**:Gómez-Reino, J.J., et al.

**摘要**:该临床试验测试了抗CCR5抗体在类风湿性关节炎患者中的应用,结果显示其通过抑制炎症细胞迁移显著缓解关节肿胀和疾病活动度。

---

**注**:以上文献为示例性内容,实际引用时请核对真实性和完整性,建议通过PubMed或Google Scholar检索最新研究。

       

背景信息

CD195. also known as CCR5. is a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family. It is primarily expressed on immune cells, including T lymphocytes, macrophages, and dendritic cells, and plays a key role in mediating cell migration and inflammatory responses by binding to chemokines such as CCL3. CCL4. and CCL5. CCR5 gained prominence due to its role as a co-receptor for HIV-1 entry into host cells, making it a critical target in HIV research and therapeutic development.

CD195 antibodies are immunological tools designed to detect or modulate CCR5 activity. They are widely used in flow cytometry, immunohistochemistry, and functional studies to characterize CCR5 expression patterns, track immune cell subsets, or block receptor-ligand interactions. Specific clones (e.g., 2D7/CCR5) recognize distinct epitopes, with some exhibiting neutralizing capabilities to inhibit HIV infection or inflammatory signaling. These antibodies have also contributed to understanding CCR5's involvement in autoimmune diseases, cancer metastasis, and transplant rejection.

Clinically, CCR5 antagonists like maraviroc (derived from antibody-guided research) are approved for HIV treatment. Additionally, CRISPR-based CCR5 gene editing has been explored for HIV cure strategies. Recent studies further link CCR5 to tumor microenvironment regulation, expanding its relevance in oncology. The Δ32 mutation, a natural CCR5 variant conferring HIV resistance, underscores its biological and therapeutic significance. CD195 antibodies remain pivotal in both basic research and translational efforts targeting immune dysregulation and infectious diseases.

       
关键字: CD195抗体;CD195;CD195 Antibody;

公司简介

湖北瑞和宁生物科技有限公司研究创新能力, 拥有完整、科学、质量管理体系。并不断致力于技术创新,产品创新和管理创新,赢得了国内外广大用户的信任。
成立日期 2024-06-24 (2年) 注册资本 50万(元)
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 中间体,化学试剂 经营模式 贸易,工厂,试剂,定制,服务
  • 湖北瑞和宁生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:50万(元)
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:中间体。试剂
  • 公司地址:江汉区
询盘

店内推荐

CD195抗体相关厂家报价

产品名称 价格   公司名称 报价日期
询价
上海华盈生物医药科技有限公司
2026-02-15
询价
VIP4年
维百奥(北京)生物科技有限公司
2025-12-29
¥1800
VIP2年
费雪(杭州)医学研究有限公司
2026-01-05
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.